Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Nature Medicine

Volumn 19, Issue 12, 2013, Pages 1625-1631

  Kottke, Timothy ^a   Boisgerault, Nicolas ^a   Diaz, Rosa Maria ^a   Donnelly, Oliver ^b   Rommelfanger Konkol, Diana ^a   Pulido, Jose ^a   Thompson, Jill ^a   Mukhopadhyay, Debabrata ^c   Kaspar, Roger ^d   Coffey, Matt ^e   Pandha, Hardev ^f   Melcher, Alan ^b   Harrington, Kevin ^g   Selby, Peter ^b   Vile, Richard ^a,b  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c MAYO GRADUATE SCHOOL   (United States)

^d TransDerm   (United States)

^e ONCOLYTICS BIOTECH INC   (Canada)

^f UNIVERSITY OF SURREY   (United Kingdom)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; INNATE IMMUNITY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PRIORITY JOURNAL; TUMOR RECURRENCE;

MUS;

EID: 84889885063     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3397     Document Type: Article

References (54)

1. Aguirre-Ghiso, J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007). (Pubitemid 350006258)
2. Goss, P.E. & Chambers, A.F. Does tumour dormancy offer a therapeutic target Nat. Rev. Cancer 10, 871-877 (2010).
3. Hensel, J.A., Flaig, T.W. & Theodorescu, D. Clinical opportunities and challenges in targeting tumour dormancy. Nat. Rev. Clin. Oncol. 10, 41-51 (2013).
4. McGowan, P.M., Kirstein, J.M. & Chambers, A.F. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol. 5, 1083-1098 (2009).
5. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351 (2009).
6. Weinhold, K.J., Goldstein, L.T. & Wheelock, E.F. Tumour-dormant states established with L5178Y lymphoma cells in immunised syngeneic murine hosts. Nature 270, 59-61 (1977). (Pubitemid 8201710)
7. Weinhold, K.J., Goldstein, L.T. & Wheelock, E.F. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J. Exp. Med. 149, 732-744 (1979). (Pubitemid 9137685)
8. Weinhold, K.J., Miller, D.A. & Wheelock, E.F. The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J. Exp. Med. 149, 745-757 (1979). (Pubitemid 9137686)
9. Wikman, H., Vessella, R. & Pantel, K. Cancer micrometastasis and tumour dormancy. APMIS 116, 754-770 (2008).
10. Aguirre-Ghiso, J.A., Bragado, P. & Sosa, M.S. Metastasis awakening: targeting dormant cancer. Nat. Med. 19, 276-277 (2013).
11. Polzer, B. & Klein, C.A. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat. Med. 19, 274-275 (2013).
12. Albini, A., Tosetti, F., Li, V.W., Noonan, D.M. & Li, W.W. Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 9, 498-509 (2012).
13. Almog, N. et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 69, 836-844 (2009).
14. Indraccolo, S. et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc. Natl. Acad. Sci. USA 103, 4216-4221 (2006).
15. Murdoch, C., Muthana, M., Coffelt, S.B. & Lewis, C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618-631 (2008).
16. Ossowski, L. & Aguirre-Ghiso, J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 23, 41-56 (2010).
17. Karrison, T.G., Ferguson, D.J. & Meier, P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 91, 80-85 (1999). (Pubitemid 29042447)
18. Kovács, A.F., Ghahremani, M.T., Stefenelli, U. & Bitter, K. Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx-long-term results. J. Chemother. 15, 495-502 (2003). (Pubitemid 37330577)
19. Retsky, M.W., Demicheli, R., Hrushesky, W.J., Baum, M. & Gukas, I.D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116, 730-741 (2008).
20. Drake, C.G., Jaffee, E.M. & Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006). (Pubitemid 43765799)
21. Garrido, F., Cabrera, T. & Aptsiauri, N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 127, 249-256 (2010).
22. Kaluza, K.M. et al. Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants. Int. J. Cancer 131, 844-854 (2012).
23. Liu, K., Caldwell, S.A., Greeneltch, K.M., Yang, D. & Abrams, S.I. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J. Immunol. 176, 3374-3382 (2006). (Pubitemid 43363984)
24. Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828-835 (2007). (Pubitemid 47038194)
25. Sanchez-Perez, L. et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65, 2009-2017 (2005). (Pubitemid 40478631)
26. Kaluza, K.M. et al. Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum. Gene Ther. 23, 1054-1064 (2012).
27. Kottke, T. et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 16, 1910-1918 (2008).
28. Rommelfanger, D.M. et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 72, 4753-4764 (2012).
29. Wongthida, P. et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. 22, 1343-1353 (2011).
30. Kottke, T. et al. Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol. Ther. 19, 1802-1812 (2011).
31. Kottke, T. et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J. Clin. Invest. 120, 1551-1560 (2010).
32. Kottke, T. et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat. Med. 17, 854-859 (2011).
33. Pulido, J. et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat. Biotechnol. 30, 337-343 (2012).
34. Melcher, A. et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4, 581-587 (1998). (Pubitemid 28237357)
35. Sanchez-Perez, L. et al. Synergy of adoptive T-cell therapy with intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther. 14, 998-1009 (2007). (Pubitemid 46965269)
36. Vile, R.G. et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a TH1-like profile of intratumoural cytokine expression. Int. J. Cancer 71, 267-274 (1997). (Pubitemid 27253001)
37. Vile, R.G., Nelson, J.A., Castleden, S., Chong, H. & Hart, I.R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234 (1994). (Pubitemid 24378658)
38. Karapanagiotou, E.M. et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin. Cancer Res. 18, 2080-2089 (2012).
39. Dranoff, G. Experimental mouse tumour models: what can be learnt about human cancer immunology Nat. Rev. Immunol. 12, 61-66 (2011).
40. Cray, C. Acute phase proteins in animals. Prog. Mol. Biol. Transl. Sci. 105, 113-150 (2012).
41. Cray, C., Zaias, J. & Altman, N.H. Acute phase response in animals: a review. Comp. Med. 59, 517-526 (2009).
42. Stadnyk, A.W. & Gauldie, J. The acute phase protein response during parasitic infection. Immunol. Today 12, A7-A12 (1991). (Pubitemid 121002451)
43. Gonzalez-Gonzalez, E. et al. Visualization of plasmid delivery to keratinocytes in mouse and human epidermis. Sci. Rep. 1, 158 (2011).
44. Mukhopadhyay, D., Knebelmann, B., Cohen, H.T., Ananth, S. & Sukhatme, V.P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell Biol. 17, 5629-5639 (1997). (Pubitemid 27357659)
45. Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003). (Pubitemid 37040391)
46. Lichty, B.D., Power, A.T., Stojdl, D.F. & Bell, J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10, 210-216 (2004). (Pubitemid 38581793)
47. Russell, S.J., Peng, K.W. & Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012).
48. Boisgerault, N. et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol. Ther. 21, 1507-1516 (2013).
49. Duren, M. et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high-and low-risk patients. Surgery 126, 13-19 (1999). (Pubitemid 29340686)
50. Kloos, R.T. & Mazzaferri, E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J. Clin. Endocrinol. Metab. 90, 5047-5057 (2005). (Pubitemid 41262253)
51. Cooper, D.S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
52. Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718 (2006). (Pubitemid 43247141)
53. Tarhini, A.A., Gogas, H. & Kirkwood, J.M. IFN in the treatment of melanoma. J. Immunol. 189, 3789-3793 (2012).
54. Hogquist, K.A. et al. T cell receptor antagonistic peptides induce positive selection. Cell 76, 17-27 (1994). (Pubitemid 24035278)